Sleep disturbance is common in peri- and postmenopausal women, even in the absence of VMS, and is independently linked to worse quality of life, depression, and anxiety.
How should psychiatrists think about hormone therapy in perimenopause? This article explains when, why, and how to consider MHT for perimenopausal women with mood and anxiety symptoms.
Current guidelines list gabapentin as a recommended nonhormonal therapy for vasomotor symptoms in women who cannot or prefer not to use hormone therapy.
While some antidepressants may affect the metabolism of tamoxifen into its active form, many antidepressants can be used safely in this population.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
This review and meta-analysis reviews the effectiveness of cognitive behavioral therapy and mindfulness interventions for depression, anxiety, and cognitive functioning in women undergoing menopausal transition. Â
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
Menopause is a period of increased risk for women with schizophrenia spectrum disorders, and women are at higher risk for relapse than their age-matched male counterparts.
While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
